ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

43.20
-0.20
(-0.46%)
Closed December 05 4:00PM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
43.20
Bid
41.00
Ask
42.00
Volume
542
43.20 Day's Range 43.80
21.40 52 Week Range 58.50
Previous Close
43.40
Open
43.80
Last Trade
47
@
43.2
Last Trade Time
Average Volume (3m)
114
Financial Volume
-
VWAP
-

2GH Latest News

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus...

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10043.247437546.60089286DE
4-6.8-13.65051.540.49946.46118598DE
12-2.2-4.8458149779745.451.540.411447.6509915DE
26-3.4-7.2961373390646.657.540.415348.80237835DE
5221.800001101.86916831221.39999958.521.39999917044.3573342DE
15619.481.51260504223.858.51916541.98058262DE
26019.481.51260504223.858.51916541.98058262DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
17DArcadia Biosciences Inc
5.15 €
(99.61%)
10.94k
1KPAProtara Therapeutics Inc
5.90 €
(75.60%)
16.79k
1ZY0Medaro Mining Corp
0.17 €
(63.46%)
54.1k
TE9Teco 2030 ASA
0.0398 €
(61.79%)
1.04M
L7C2Windfall Geotek Inc
0.006 €
(50.00%)
18k
NL8Genesis Ai Corp
0.0056 €
(-58.82%)
10k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
859
CNWCodon AG
0.0065 €
(-40.91%)
1.5k
BLEBluebird bio Inc
0.4205 €
(-40.13%)
233.06k
DW8Tantalex Lithium Resources Corp
0.0115 €
(-39.47%)
2k
D7GNel ASA
0.2679 €
(0.15%)
5.5M
AXIAtos SE
0.20 €
(-36.51%)
4.95M
PLUNPlug Power Inc
2.2955 €
(13.55%)
3.17M
R9BDeFi Technologies Inc
3.06 €
(-6.13%)
2.98M
TUI1Tui AG
8.318 €
(5.26%)
2.21M

Discussion

View Full Feed
Dingbatt Dingbatt 2 minutes ago
Moe
I was right about gps on the electric bike but if there are no finger prints there should be sweat on the bicycle seat from peddling
GNCP
chainma1l chainma1l 2 minutes ago
Remember when I said I had concerns about the share structure?
IVFH
Think1st Think1st 3 minutes ago
Sustained income from sales will drive stock up.
NOT quick pr that they signed a contract.

Thats good only for hype ( I will take it)
It's the steady income and that comes months later 2026 -2027
Jmo
LWLG
Lime Time Lime Time 3 minutes ago
Many more fun trading days coming.

Oh the McRib yummy, need to leave the house and get me one of those cancer sandwiches 🤣 😆
HMBL
flipper44 flipper44 3 minutes ago
Yes. IMO, Assuming 60 day response.
NWBO
flipper44 flipper44 3 minutes ago
Yes. IMO, Assuming 60 day response.
NWBO
uksausage uksausage 3 minutes ago
thank you kingrichard!
makes for interesting reading the timeline of its production is interesting as it started 3 months after conditional approval but only took a few months - I have been involved with Environmental assessments which took 2 years!
PLUG
dstock07734 dstock07734 4 minutes ago
EX,

You should know I was the one who first mentioned about BCG. Your talking point is boring. If you talk about the possible replacement, I might have interest.
BCG
crowin crowin 4 minutes ago
did you see my .0015 sells right before close today? Holding a bunch just in case they uplist to NASDAQ

https://investorshub.advfn.com/boards/manage_msg.asp?message_id=175483793

those .0012 sells i i had earlier today were to add cash to buy RDAR at .006-.007 for my up
RDAR
meixatech meixatech 4 minutes ago
Pattern sensitivity of ampakine-hypoxia interactions for evoking phrenic motor facilitation in anesthetized rat

Prajwal P. Thakre and David D. Fuller*

Journal of Neurophysiology - preprint
20 DEC 2023 https://doi.org/10.1152/jn.00315.2023

Repeate
RSPI
sab63090 sab63090 4 minutes ago
Hoskuld......that seems to be the best way to approach it now!
AVXL
x993231 x993231 5 minutes ago
You can not get blood from a stone.   I prefer they concentrate all efforts and money moving this forward.  If true of course they would have sent a letter.

I'm not worried about it.

X
LWLG
georgebailey georgebailey 5 minutes ago
I cannot keep up on this- is it more likely than not, December?
Assuming 60 day response.
NWBO
op1 op1 6 minutes ago
Bad close
Nothing changed
Orders below bid ….but not bidding up
Still bullish but getting tired holding the only now losing position in the portfolio
WDDD
dstock07734 dstock07734 6 minutes ago
EX,

When can you learn? Everyone working on DC vaccine for cancer would love to have DCs load tumor-associated antigens as many as possible. Why cannot you grasp such as simple idea? It is intuitive the more target information is provided for immune system, the better the efficacy is.
NWBO
sab63090 sab63090 6 minutes ago
Citrati
Thanks for your comments and your impressions, too! I will take issue with it not being a double top though...the price does not have to be exactly to the prior high but rather near it. You are correct that it was slightly below the prior high (we used to label it "a hook" in commod
crazy horse 0 crazy horse 0 7 minutes ago
VERY SERIOUS!! There are two Russian bases or territories in Syria. If the US takes them it will be the second time the US has invaded Russia, the first being Kursk.


Those increasingly look to be the end game objectives of this operation.
Regarding developing events in
Viewmont Viewmont 8 minutes ago
$RDAR Don't leave Ouzo out! 😃
RDAR
Filterthenoise Filterthenoise 8 minutes ago
Any relation?
trade15 trade15 9 minutes ago
1manband

Was the Waaco Kid before or after Leroy Stockmans ? I know Waaco was before George Chelekis and Silicon Investor. I also remember the name Bill Demorrow.

Trade15
Hoskuld Hoskuld 9 minutes ago
sab, IMO this is all about news now: MAA acceptance, peer review, PD trial start, Rett trial start, Schizo read out, etc. Your TA is really interesting and I appreciate it - and at the same time just waiting on material developments to drive this to the next level.
AVXL
dewophile dewophile 9 minutes ago
I have money set aside for after the data release if I think the market reaction is inappropriate. I do already have a large position (although smaller now at 8 dollars)
ENTA
Lonewolf1 Lonewolf1 9 minutes ago
Exactly right. This is the right place and the right time for this ticker to make a huge run.

Management needs to understand this, and I can't believe they don't.

Patience....
CGAC
alertmeipp alertmeipp 9 minutes ago
It almost feels like management is trolling us lol

Dec 9 is Monday. So technically, it is still 2 business days.
RVNC
Mufaso Mufaso 9 minutes ago
AMGN had two investor webcasts this week (Evercore and Citi) in which most of the discussion was focused on MariTide. I would strongly suggest that you listen to one or both of them.

Your suggestion in your message was a good one but I thought I would respond to it as a separate reply
AMGN

Your Recent History

Delayed Upgrade Clock